Rhodococcus Equi Pneumonia: What the Research Says
Evidence from 22 peer-reviewed studies
What Professionals Should Know
- •Rhodococcus equi hyperimmune plasma can reduce severity of pneumonia in neonatal foals and may be indicated for high-risk foals on farms with endemic R equi
- •Since no vaccine is available, HIP remains a practical option for passive immunization against R equi in foals at risk
- •Consider HIP administration protocols on farms with confirmed R equi disease history to mitigate clinical impact in affected foals
- •Oral vaccination with eBeam-inactivated R. equi at the tested doses and intervals does not provide reliable protection against R. equi pneumonia in foals—alternative strategies are needed.
- •The failure of this approach, despite theoretical immunogenicity, highlights the challenge of developing effective R. equi vaccines and the need for further research before clinical adoption.
- •Current disease management in R. equi-endemic operations should continue to rely on early detection and antibiotic treatment rather than vaccination with this formulation.
- •Baseline biomarker profiling (cortisol, vitamin D, cytokines) in neonatal foals could help identify high-risk individuals for severe Rhodococcus equi pneumonia on endemic farms
- •Early detection of altered immune/endocrine profiles may enable targeted preventive interventions or closer monitoring of susceptible foals
- •These biomarkers could complement clinical assessment to stratify disease severity and guide treatment intensity in pneumonic foals
- •Rectal swab qPCR cannot yet be reliably used as a standalone diagnostic tool for R. equi pneumonia in foals; traditional clinical and diagnostic methods remain necessary
- •While fecal qPCR shows promise as a research and screening tool, the 79-83% accuracy rates mean approximately 1 in 5 results may be misleading in clinical practice
- •This test may have potential value as part of a diagnostic algorithm alongside clinical signs, imaging, and culture, but further development is needed before clinical adoption
- •Withholding antibiotic treatment for foals with small pulmonary lesions on ultrasound does not increase mortality risk and significantly reduces unnecessary antimicrobial exposure
- •Use of serial ultrasonographic monitoring to measure abscess burden provides objective criteria for initiating treatment in suspected R. equi cases rather than treating all cases empirically
- •This evidence supports selective treatment strategies to combat antimicrobial resistance while maintaining equivalent safety outcomes in foal pneumonia management
- •On farms with endemic R. equi, expect that roughly 1 in 4 foals may develop clinical disease; risk is not uniform across all foals
- •Prior health challenges in foals may alter susceptibility to R. equi, suggesting immune or management factors warrant investigation
- •Year-to-year variation in disease incidence on the same farm indicates environmental or management factors are modifiable—investigate annual changes in housing, stocking density, or hygiene protocols
- •VapA-specific IgG ELISA alone is insufficient for reliable diagnosis of R. equi pneumonia in clinical practice; consider IgG subclass analysis or alternative diagnostic methods
- •Serological testing should be used alongside clinical signs, imaging, and other diagnostic tools rather than as a standalone screening test for foal pneumonia
- •Understanding IgG subclass responses may help refine diagnostic protocols for identifying R. equi infection in at-risk foal populations
- •Weekly SAA testing alone is not recommended as an early screening tool before clinical signs appear; reserve SAA testing for monitoring treatment response once pneumonia is confirmed
- •Consider implementing weekly plasma fibrinogen monitoring from 1 week of age as a potential cost-effective screening protocol, pending establishment of age-appropriate reference intervals
- •Continue relying on thoracic ultrasonography as the primary early diagnostic method until fibrinogen reference intervals are established and validated in practice
- •Early fecal microbiome assessment cannot be used to predict which foals will develop R. equi pneumonia, so clinicians must rely on other risk factors and clinical vigilance
- •Microbiome diversity in neonatal foals does not appear to be a protective factor against R. equi infection during the period when foals are most susceptible
- •Management focus should remain on established prevention strategies rather than microbiome-based risk stratification at 3-5 weeks of age
- •Genetic predisposition influences R. equi pneumonia susceptibility in foals; consider family history and breeding decisions at high-risk farms
- •Some foals develop subclinical pulmonary lesions without clinical signs—ultrasound screening may identify at-risk individuals warranting closer monitoring or preventive management
- •Immune function (neutrophil-related) appears to be a key genetic factor; future management strategies might target immune competence during the critical foal rearing period
- •Stables pose substantially higher infection risk than paddocks for R. equi pneumonia — prioritize stable management if your farm has had disease cases
- •Focus on improving ventilation, switching to less dust-producing bedding, and consider fogging protocols to reduce airborne virulent organism concentrations
- •Environmental contamination in stables is a modifiable risk factor — these management changes are practical steps to reduce foal pneumonia outbreaks on breeding farms
- •Genetic testing for the -57C/T variant may help identify foals at higher risk for R. equi pneumonia, allowing for targeted preventive management strategies
- •Understanding individual foal genetic susceptibility to R. equi could inform breeding decisions on farms with endemic disease pressure
- •This research suggests that not all foal exposure to environmental R. equi results in clinical disease due to underlying genetic variation in innate immunity
- •SAA can aid in differentiating bacterial from non-bacterial infections in neonatal foals, particularly those presenting with weakness—normal SAA suggests non-bacterial disease and better prognosis
- •SAA normalizes faster than traditional markers (fibrinogen, WBC count) during recovery from Rhodococcus equi pneumonia, making it useful for monitoring treatment response and discharge planning
- •SAA is not reliably useful for evaluating foals with diarrhoea as the primary sign, regardless of rotavirus status, so should be combined with other diagnostic approaches for this condition
- •Nasotracheal aspiration can be used as a reliable first-line diagnostic tool for R. equi pneumonia in foals, with detection rates similar to the more invasive transtracheal aspiration technique
- •The low contamination rate from nasopharyngeal flora means positive cultures from nasotracheal aspirates are clinically meaningful and unlikely to represent contamination alone
- •Consider nasotracheal aspiration as the preferred sampling method in practice due to its noninvasive nature, safety profile, and comparable diagnostic accuracy
- •Hyperimmune plasma's clinical benefit in preventing foal R. equi pneumonia likely does not work through direct enhancement of alveolar macrophage function, suggesting other protective mechanisms may be involved
- •Normal plasma appears equally effective as hyperimmune plasma at opsonizing R. equi in vitro, questioning the additional cost and logistics of hyperimmune plasma use for this indication
- •Any clinical advantage of hyperimmune plasma over standard plasma for R. equi prevention in foals must involve mechanisms beyond macrophage-mediated killing, such as systemic immunity or other immune pathways
- •R. equi remains a significant cause of foal mortality with no available vaccine; understanding immune mechanisms is critical for developing prevention strategies
- •Foal age and immune maturity are key risk factors—young foals with naive immune systems require special management and monitoring protocols
- •Stimulating innate immune responses through live vaccines and immunomodulation may offer practical pathways to reduce pneumonia incidence in foals
- •Understanding VapA's cell surface localization mechanism may inform development of targeted therapeutics or vaccines against R. equi pneumonia in foals, since VapA creates the intracellular niche essential for bacterial survival
- •The finding that soluble recombinant VapA can functionally complement native VapA suggests potential for novel immunotherapeutic or antimicrobial approaches in clinical practice
- •Monitor WBC, neutrophil, monocyte counts and fibrinogen levels during azithromycin-rifampicin treatment as these markers show clear improvement by day 14 and may help assess treatment response
- •Rising IL-2 and IL-10 levels during treatment appear associated with clinical improvement, suggesting these markers may help practitioners evaluate whether the immune system is mounting an appropriate response
- •Individual interferon measurements alone are not reliable diagnostic or prognostic markers for R. equi pneumonia—focus on the pattern of multiple inflammatory markers rather than single values
- •Reconsider routine antimicrobial treatment of subclinically affected foals on your farm; this practice drives MDR-R. equi emergence with limited treatment alternatives available
- •Implement targeted ultrasound screening protocols but reserve antimicrobial therapy for clinically affected foals rather than prophylactic treatment of all detected cases
- •Collaborate with your veterinarian to develop farm-specific antimicrobial stewardship plans that balance disease prevention with resistance mitigation
- •Hyperimmune plasma can help reduce R. equi pneumonia incidence on endemic farms, but standardized protocols for dosing and timing are lacking—consult current farm data and veterinary guidance for your operation
- •Consider the significant costs and labor requirements of hyperimmune plasma transfusion when evaluating disease prevention strategies; explore emerging alternatives as they become available
- •Screen foals receiving hyperimmune plasma for transfusion reactions and complications, as this is an invasive procedure with documented risks
- •While early screening and treatment reduce mortality in foals, practitioners must balance benefits against contribution to antimicrobial resistance; judicious use of screening protocols is warranted
- •Macrolide plus rifampin remains your first-line treatment for confirmed R. equi pneumonia, but ongoing research may identify superior combinations—stay updated with new evidence
- •Passive immunisation (hyperimmune serum) is your best current prevention tool for high-risk foals, though cost and logistics require careful management planning and client communication about realistic effectiveness
- •BALF cytology showing elevated neutrophils with reduced macrophages suggests R. equi pneumonia in young foals with respiratory disease, allowing earlier targeted treatment decisions before culture confirmation
- •Bronchoalveolar lavage is a practical field procedure requiring minimal equipment that can help differentiate R. equi from other bacterial causes of foal pneumonia
- •Consider R. equi as a likely diagnosis in foals aged 3 weeks to 6 months presenting with pneumonia and elevated neutrophil/reduced macrophage proportions on BALF analysis
Key Research Findings
Hyperimmune plasma treatment decreased pneumonia severity in experimentally challenged neonatal foals
R equi-specific hyperimmune plasma demonstrated protective efficacy against clinical rhodococcal infection
Results support the use of commercially available HIP as a preventive intervention in at-risk neonatal foals
Oral eBeam-inactivated R. equi vaccination did not protect foals from pneumonia, with 88% of vaccinated foals (7/8) developing disease versus 75% of controls (3/4).
The vaccination regimen administered at days 2, 7, and 14 failed to generate protective immunity despite prior evidence that eBeam-inactivated bacteria are structurally intact and immunogenic.
Alternative dosing schedules and routes of administration warrant investigation as the current protocol was ineffective.
Cortisol and vitamin D concentrations vary with age in foals from birth to weaning and may be influenced by disease status
Circulating cytokine profiles differ between healthy and pneumonic foals affected by Rhodococcus equi
Combined assessment of steroid hormones and cytokines may have predictive value for respiratory disease severity in endemic farm settings
qPCR of rectal swabs showed 79.5% sensitivity and 83.0% specificity for detecting R. equi pneumonia at a threshold of 14,883 vapA copies per 100 ng fecal DNA
Area under the ROC curve was 83.7% (95% CI, 74.9-92.6), indicating moderate diagnostic accuracy
Fecal concentrations of virulent R. equi were significantly higher in pneumonic foals than healthy foals from the same environment
Despite significant differences between groups, qPCR of rectal swabs lacks adequate diagnostic accuracy for clinical use
Antibiotic treatment was reduced from 81.5% of foals with R. equi pneumonia (2008-2011) to 50.9% (2012-2016) by implementing selective treatment criteria based on abscess size
Median abscess score at treatment initiation increased from 4 cm² to 11.5 cm² between the two periods without changing treatment thresholds
Evidence Base
Rhodococcus equi hyperimmune plasma decreases pneumonia severity after a randomised experimental challenge of neonatal foals.
Sanz M G, Loynachan A, Horohov D W (2016) — The Veterinary record
Oral Administration of Electron-Beam Inactivated Rhodococcus equi Failed to Protect Foals against Intrabronchial Infection with Live, Virulent R. equi.
Rocha Joana N, Cohen Noah D, Bordin Angela I et al. (2016) — PloS one
The potential value of cytokine, cortisol and vitamin D profiles in foals from birth to weaning for respiratory disease prediction on a farm endemic for Rhodococcus equi pneumonia.
Berghaus Londa J, Venner Monica, Helbig Hannah et al. (2026) — Equine veterinary journal
Fecal concentration of Rhodococcus equi determined by quantitative polymerase chain reaction of rectal swab samples to differentiate foals with pneumonia from healthy foals.
Cohen Noah D, Flores-Ahlschewde Patricia, Gonzales Giana M et al. (2022) — Journal of veterinary internal medicine
Changing policy to treat foals with Rhodococcus equi pneumonia in the later course of disease decreases antimicrobial usage without increasing mortality rate.
Arnold-Lehna Denise, Venner Monica, Berghaus Londa J et al. (2020) — Equine veterinary journal
Foal-Level Risk Factors Associated With Development of Rhodococcus equi Pneumonia at a Quarter Horse Breeding Farm.
Coleman Michelle C, Blodgett Glenn P, Bevevino Kari E et al. (2019) — Journal of equine veterinary science
Validation and evaluation of VapA-specific IgG and IgG subclass enzyme-linked immunosorbent assays (ELISAs) to identify foals with Rhodococcus equi pneumonia.
Sanz M G, Oliveira A F, Loynachan A et al. (2016) — Equine veterinary journal
Rhodococcus equi pneumonia in foals: an assessment of the early diagnostic value of serum amyloid A and plasma fibrinogen concentrations in equine clinical practice.
Passamonti F, Vardi D M, Stefanetti V et al. (2015) — Veterinary journal (London, England : 1997)
Composition and Diversity of the Fecal Microbiome and Inferred Fecal Metagenome Does Not Predict Subsequent Pneumonia Caused by Rhodococcus equi in Foals.
Whitfield-Cargile Canaan M, Cohen Noah D, Suchodolski Jan et al. (2015) — PloS one
Identification of genomic loci associated with Rhodococcus equi susceptibility in foals.
McQueen Cole M, Doan Ryan, Dindot Scott V et al. (2014) — PloS one
Comparison of concentrations of Rhodococcus equi and virulent R. equi in air of stables and paddocks on horse breeding farms in a temperate climate.
Muscatello G, Gerbaud S, Kennedy C et al. (2006) — Equine veterinary journal
Variations in equid SLC11A1 (NRAMP1) genes and associations with Rhodococcus equi pneumonia in horses.
Halbert Natalie D, Cohen Noah D, Slovis Nathan M et al. (2006) — Journal of veterinary internal medicine
Serum amyloid A (SAA) as an aid in the management of infectious disease in the foal: comparison with total leucocyte count, neutrophil count and fibrinogen.
Hultén C, Demmers S (2002) — Equine veterinary journal
Evaluation of nasotracheal aspiration as a diagnostic tool for Rhodococcus equi pneumonia in foals.
Hashikura S, Higuchi T, Taharaguchi S et al. (2000) — Equine veterinary journal
Opsonization but not pretreatment of equine macrophages with hyperimmune plasma nonspecifically enhances phagocytosis and intracellular killing of Rhodococcus equi.
Harvey Aja B, Bordin Angela I, Rocha Joana N et al. (2021) — Journal of veterinary internal medicine
Protective immune response against Rhodococcus equi: An innate immunity-focused review.
da Silveira Bibiana Petri, Cohen Noah D, Lawhon Sara D et al. (2025) — Equine veterinary journal
The N-terminal domain is required for cell surface localisation of VapA, a member of the Vap family of Rhodococcus equi virulence proteins.
Miranda-CasoLuengo Raúl, Yerlikaya Zeynep, Luo Haixia et al. (2024) — PloS one
Monitoring of inflammatory blood biomarkers in foals with Rhodococcus Equi pneumonia during antimicrobial treatment.
Deniz Ömer, Ekinci Gencay, Onmaz Ali Cesur et al. (2024) — Journal of equine veterinary science
Rhodococcus Equi: Challenges to Treat Infections and to Mitigate Antimicrobial Resistance.
Higgins Courtney, Huber Laura (2023) — Journal of equine veterinary science
Transfusion of hyperimmune plasma for protecting foals against Rhodococcus equi pneumonia.
Kahn Susanne K, Cohen Noah D, Bordin Angela I et al. (2023) — Equine veterinary journal
Show 2 more references
Rhodococcus equi foal pneumonia: Update on epidemiology, immunity, treatment and prevention.
Bordin Angela I, Huber Laura, Sanz Macarena G et al. (2022) — Equine veterinary journal
Cytological Findings in Bronchoalveolar Lavage Fluid of Foals With Pneumonia Caused by Rhodococcus equi and Other Bacteria.
Vitale Valentina, Sgorbini Micaela, Cuteri Vincenzo et al. (2019) — Journal of equine veterinary science